Literature DB >> 11888027

Association of parental vaccination reports with measles, mumps, and rubella protective antibody levels: comparison of Somali immigrant, Hispanic migrant, and US children in Rochester, Minn.

Jennifer L St Sauver1, Robert M Jacobson, Robert A Vierkant, Steven J Jacobsen, Erin M Green, Gregory A Poland.   

Abstract

OBJECTIVES: To compare measles, mumps, and rubella antibody levels in Somali immigrant, Hispanic migrant, and US children in Rochester, Minn, and to determine whether parental vaccination reports predict seropositivity. SUBJECTS AND METHODS: From 1995 to 1997, we conducted a cross-sectional analysis using measles, mumps, and rubella antibody levels obtained from a sample of Somali, Hispanic, and Rochester children. Volunteers provided blood samples, vaccination histories, and demographic information. We assessed differences in measles, mumps, and rubella antibody levels among the 3 groups of children and calculated positive and negative predictive values to determine whether parental report of vaccination predicted seropositivity.
RESULTS: Study participants included 79 Hispanic migrant, 69 Somali immigrant, and 730 Rochester children. Somali children reported vaccination at significantly older ages compared with Hispanic or Rochester children (P<.001). Most children were seropositive for all 3 antibodies. Parental reports of vaccination had high positive predictive values (71%-100%) but low negative predictive values (0%-50%).
CONCLUSION: Somali and Hispanic children were as likely as Rochester children to be seropositive for measles, mumps, and rubella antibodies despite poor documentation of vaccination. Somali children, however, tended to receive vaccinations at significantly older ages than Hispanic and Rochester children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888027     DOI: 10.4065/77.3.241

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  Incomplete immunity and missed vaccination opportunities in East African immigrants settling in Australia.

Authors:  Susan A Skull; Joanne Y Y Ngeow; Geoff Hogg; Beverley-Ann Biggs
Journal:  J Immigr Minor Health       Date:  2008-06

2.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

3.  Completion of the human papillomavirus vaccination series lags in Somali adolescents.

Authors:  Crystal N Pruitt; Crystal S Reese; Brandon R Grossardt; Abdirashid M Shire; Douglas J Creedon
Journal:  J Low Genit Tract Dis       Date:  2013-07       Impact factor: 1.925

4.  Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population.

Authors:  N Dhiman; I G Ovsyannikova; R A Vierkant; V S Pankratz; R M Jacobson; G A Poland
Journal:  Tissue Antigens       Date:  2008-09

5.  Elevated antimeasles antibody titre: An association in autoimmune encephalitis.

Authors:  S R Chandra; Thomas Gregor Issac; Mariamma Philip; A Krishnan
Journal:  J Neurosci Rural Pract       Date:  2015 Oct-Dec

6.  Asthma and the immune response to MMR vaccine viruses in Somali immigrant children: a cross-sectional retrospective cohort study.

Authors:  Apurvi R Patel; John Zietlow; Robert M Jacobson; Gregory A Poland; Young J Juhn
Journal:  Prim Care Respir J       Date:  2013-09

Review 7.  A Scoping Review of the Health of African Immigrant and Refugee Children.

Authors:  Bukola Salami; Higinio Fernandez-Sanchez; Christa Fouche; Catrin Evans; Lindiwe Sibeko; Mia Tulli; Ashley Bulaong; Stephen Owusu Kwankye; Mary Ani-Amponsah; Philomina Okeke-Ihejirika; Hayat Gommaa; Kafuli Agbemenu; Chizoma Millicent Ndikom; Solina Richter
Journal:  Int J Environ Res Public Health       Date:  2021-03-28       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.